Harnessing big data to characterize immune-related adverse events
Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are
associated with a unique spectrum of organ-specific inflammatory toxicities known as …
associated with a unique spectrum of organ-specific inflammatory toxicities known as …
Cutaneous manifestations associated with immune checkpoint inhibitors
T Watanabe, Y Yamaguchi - Frontiers in Immunology, 2023 - frontiersin.org
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block key mediators of
tumor-mediated immune evasion. The frequency of its use has increased rapidly and has …
tumor-mediated immune evasion. The frequency of its use has increased rapidly and has …
Association of cutaneous immune-related adverse events with increased survival in patients treated with anti–programmed cell death 1 and anti–programmed cell …
Importance Despite the efficacy of immune checkpoint inhibitors (ICIs), cutaneous immune-
related adverse events (cirAEs) occur in 20% to 40% of all treated patients. To our …
related adverse events (cirAEs) occur in 20% to 40% of all treated patients. To our …
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi …
Background Cutaneous immune-related adverse events (cirAEs) occur in up to 40% of
immune checkpoint inhibitor (ICI) recipients. However, the association of cirAEs with survival …
immune checkpoint inhibitor (ICI) recipients. However, the association of cirAEs with survival …
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
Background Understanding co-occurrence patterns and prognostic implications of immune-
related adverse events is crucial for immunotherapy management. However, previous …
related adverse events is crucial for immunotherapy management. However, previous …
Treatment of rheumatic adverse events of cancer immunotherapy
P Reid, LC Cappelli - Best Practice & Research Clinical Rheumatology, 2022 - Elsevier
Immune checkpoint inhibitors (ICIs), used to treat many advanced cancers, activate the
immune system to elicit an antitumor response. ICIs can also cause immune-related adverse …
immune system to elicit an antitumor response. ICIs can also cause immune-related adverse …
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience
M Merli, M Accorinti, M Romagnuolo, A Marzano… - Frontiers in …, 2023 - frontiersin.org
Cutaneous immune-related adverse events are frequently associated with immune
checkpoint inhibitors (ICIs) administration in cancer patients. In fact, these monoclonal …
checkpoint inhibitors (ICIs) administration in cancer patients. In fact, these monoclonal …
Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor …
Background Emerging evidence suggests that cutaneous immune-related adverse events
(cirAEs) are associated with a survival benefit in the setting of advanced melanoma treated …
(cirAEs) are associated with a survival benefit in the setting of advanced melanoma treated …
High grade dermatologic adverse events associated with immune checkpoint blockade for cancer
AM Kuo, A Markova - Frontiers in Medicine, 2022 - frontiersin.org
Immune checkpoint blockade (ICB) improves survival in many types of cancers including
melanoma, non-small cell lung, renal cell, breast, and cervical cancers. However, many of …
melanoma, non-small cell lung, renal cell, breast, and cervical cancers. However, many of …
Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions
Importance Serious cutaneous adverse drug reactions (cADRs) are potentially life-
threatening drug hypersensitivity reactions involving the skin and internal organs. Antibiotics …
threatening drug hypersensitivity reactions involving the skin and internal organs. Antibiotics …